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1. Summary 
 
This thesis concerns the linking together of the challenges encountered in the economic 
evaluation of medical devices and credible ways of performing economic evaluation in such 
a scenario. Although the standard methods of estimating cost-effectiveness have gained 
widespread acceptance, there are concerns around the methods for conducting economic 
evaluation in the health technology assessment of devices. Currently, the lack of 
appropriate comparators and evidence generation (i.e. quantity and quality of the clinical 
and economic evidence) have been identified as the main challenges.  
The four publications associated with this thesis explore the validity and applicability of 
methods which have the potential to overcome these challenges. These methods include: 
undertaking economic evaluation by classifying devices based on their granularity and 
clinical relevance; construction of artificial comparator; time-to-event analysis; propensity 
score matching; covariate adjustments; and sensitivity analysis for device cost and health 
related quality of life (HRQoL) estimates. The first and second publications (studies I & II) 
draw upon the British Blood and Transplant Database (BTDB), which holds individual 
patient level data collected from the six designated British centres responsible for left 
ventricular assist device (LVAD) implantation and heart transplant (HT). The database 
holds the medical histories of patients with advanced heart failure on the waiting list for 
HT, and recipients of LVAD implants and post-HT between May 2002 and December 2011. 
The economic evaluation for LVADs used a Markov multi-state model to assess the cost-
effectiveness of the devices. For this model, transition probabilities between health states 
were modelled using Kaplan–Meier (KM) time-to-event analyses with extrapolation 
beyond the observed data. Health outcomes were measured in quality-adjusted life years 
(QALYs) and NHS and personal social service (PSS) resource use and costs were included. 
Transition probabilities for the control arm were also estimated by constructing an 
artificial “control arm”. This artificial control arm was used to attain the statistical impact 
of a two-armed randomised trial. The two studies revealed that LVADs considered as a 
Bridge to Transplant (BTT) yields incremental cost-effectiveness ratio (ICERs) of £55,173 
per QALY, when compared with Medical Management (MM). Although LVADs were not 
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considered cost-effective at the National Institute of Health and Care Excellence’s (NICE) 
standard willingness to pay (WTP) thresholds, they clearly demonstrated an improvement 
in HRQoL and functional status for patients who survive implantation of a LVAD as a BTT. 
Our study estimated the cost-effectiveness of HW versus HMII for patients with advanced 
heart failure and showed that HW was more effective and cost-effective than HMII. The 
analyses demonstrated the credibility of economic evaluation of LVAD devices and show 
an acceptable degree of robustness in estimating the cost-effectiveness of second and 
third generation LVADs. 
 
The third and fourth publications (studies III & IV) used individual patient data from the 
National Joint Registry (NJR) for patients with osteoarthritis undergoing total hip 
replacement (THR) and resurfacing (RS) between April 2003 and December 2012. The 
database contained several different combinations of prosthesis components and these 
components were stratified by frequency of use and on expert clinical opinion. This 
process identified five categories of THR prosthesis, which were compared against each 
other; and compared against RS. The economic evaluation of hip prosthesis also used a 
Markov model to assess the cost-effectiveness of the above mentioned comparisons. For 
this model, transition probabilities between health states were modelled using KM time-
to-event analyses with extrapolation beyond the observed data. Health outcomes were 
measured in QALYs and NHS and PSS resource use and costs were used. To reduce 
selection bias due to the use of non-randomised data, we propensity (age-sex) matched 
patients from the NJR database. We identified that at a WTP £20,000 per QALY a 
cemented prosthesis with metal-on-polyethylene or ceramic-on-polyethylene bearings 
had the greatest probability of being cost-effective for all groups of age and sex over a 
lifetime. Furthermore, our study found that at a WTP of £20,000/QALY, only the 
Birmingham Hip (RS) device had a reasonable probability of being cost-effective, and even 
then only for the youngest group of men, but alternative THRs with ceramic bearing 
surface devices appeared about equally cost-effective. Our study also found that RS is not 
cost-effective over a lifetime for healthy patients and THR is shown to be the most cost-
effective option for all women and men aged over 50 years old. 
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The approaches described above improve the credibility of the cost-effectiveness estimate 
of devices; thereby assist decision makers to make informed decisions as to adopt or reject 
the technology for use in the National Health Service (NHS).  
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2. Background 
 
2.1. Medical device industry and role of regulatory bodies 
 
The UK medical device industry is an innovative industry with a long history of developing 
safe products to improve people’s health and benefit the health care sector. This industry 
was valued at $17 billion USD in 2013 and is characterised by approximately 3,300 medical 
manufacturers (ABPI, 2013), which represent some key manufacturers developing 
implantable medical devices, like Smith & Nephew, Johnson and Johnson, Medtronic and 
Thoratec Corporation to name a few (EMERGO, 2006). Medical Device Directive classify 
devices into four categories (class I, IIa, IIb, and III). Class III devices are mainly implantable 
devices and considered high risk and subject to additional conformity procedures (French-
Mowat E, 2012).  An active implantable medical device is defined by the European Union 
(EU) directive as “any active medical device which is intended to be totally or partially 
introduced, surgically or medically, into the human body or by medical intervention into a 
natural orifice, and which is intended to remain after the procedure” (EEC Council directive, 
1990). The devices are regulated under the EU law, and in the UK the Medicines & 
Healthcare Regulatory Agency (MHRA) is legally delegated by the EU to regulate medical 
devices. Therefore, MHRA is responsible to undertake post-market surveillance, whereby 
monitor any reports of adverse incidents or associated problems with use identified in the 
post-marketing phase (MHRA, 2008). However, the pre-market assessment of medical 
devices are not conducted by MHRA, but through organisations called notified bodies, 
which are accredited by member states to assess medical devices to grant conformity 
approval i.e the Conformité Européenne (CE) mark. Currently, there are 76 notified bodies 
across different EU member states to assess conformity of medical devices, which then can 
be marketed across all EU member states.  
2.2. Common differences between devices and pharmaceuticals 
 
Though pharmaceuticals and devices share same common objectives “to improve people’s 
health and benefit the health care sector”, devices differ from drugs in their mechanism of 
action, as drugs directly interact with patients by generating biochemical reactions; but 
devices rely on their physicality for treatment. A new device would undergo continuous 
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alteration throughout the lifecycle of the product, which considerably reduces the average 
product lifetime of any device. For example, it has been estimated that there are 500,000 
medical devices belonging to 10,000 generic groups with an average product lifecycle of 18 
months (Parvizi N, 2014). On the contrary, the pharmaceutical industry requires more 
intense research to develop innovative chemical entities with great research and 
development spend providing longer average product life. However, the device 
manufacturer is only required to demonstrate the safety and performance of the new 
device, as part of conformity assessment to CE mark, and is not required to conduct RCT 
studies to demonstrate the clinical efficacy of the new device. This is radically different to 
how drugs are regulated, which requires a stricter, transparent trial design to demonstrate 
the safety and efficacy of the new product before being approved by the drug regulators 
(Govin, 2006). Moreover, the EU directives on medical devices regulate devices, in contrast 
to the case with pharmaceuticals, which are regulated through a centralised regulatory 
body like the European Medicines Agency, rather than through different notified bodies 
across different EU member states (Clinical trials regualtions, 2004).These differences hold 
the basis for the dissimilarity in the process, industry composition and technology 
assessment between drugs and devices (Chapman AM, 2014).  
2.3. Reimbursement of health technologies in the UK 
 
In the UK, decisions on reimbursement of technologies are undertaken through health 
technology assessments (HTA). HTA bodies like NICE, produce guidance to publically 
funded health care systems like the NHS in England; and are also endorsed as applicable by 
Wales and Northern Ireland on the effectiveness and cost-effectiveness of new and existing 
technologies. NICE produces guidance on all technologies (i.e. pharmaceutical, medical 
devices, diagnostics and public health) through four separate appraisal programmes: 
technology, medical technologies, diagnostics and public health (NICE, 2014).  
 
Appraisal of medical technologies through the Medical Technologies Evaluation Programme 
(MTEP) was launched in 2009/2010. This is the newest NICE committee formed to develop 
medical technology guidance for suitable technologies. The technology is considered to be 
eligible to be appraised by the MTEP, if the technology has a CE mark or expected to 
receive regulatory approval and to be used in the NHS. Technologies appraised through the 
 16 
 
 
 
MTEP committee use cost-consequence analysis (CCA) (NICE, 2011). CCA is a form of 
economic analysis which measures cost and benefits in a single unit and lists the 
incremental costs and benefits, without combining these results. At times, devices could be 
considered to be appropriate to be reviewed by other guidance producing programmes 
such as a multiple technology appraisal (MTA) or non-NICE programme (HTA programme 
with no funding mandate). Technologies appraised through the other evaluation 
programmes are appraised using cost-utility analysis, where the primary outcome is cost 
per QALY. QALYs provide a common currency to assess the survival and quality of life 
benefits gained from an intervention (Weinstein MC, 2009). The cost-effectiveness of the 
intervention is then expressed using an ICER, where the increased/decreased marginal 
costs are divided by the increased/decreased marginal gains in QALYs.  
 
𝐼𝐶𝐸𝑅 =
𝐶𝑜𝑠𝑡𝐵 − 𝐶𝑜𝑠𝑡𝐴
𝑄𝐴𝐿𝑌𝐵 − 𝑄𝐴𝐿𝑌𝐴
 
The NICE reference case also recommends decision-analytical models as a standard 
framework for cost-effectiveness analysis. 
 
In summary, HTA bodies like NICE have adopted different approaches in evaluating medical 
devices due to acknowledgment of the fact that evaluations of devices are challenging in 
comparison to pharmaceuticals (Chapman AM, 2014).  
2.4. Challenges encountered in the assessment of medical devices  
 
As discussed earlier, medical devices are less regulated than pharmaceuticals, hence, the 
European Union launched the Methods for Health Technology Assessment of Medical 
Devices: A European perspective (MedtechHTA) project (Drummond M, 2016). The three 
main project recommendations were to align regulatory and HTA processes for evidence 
generation, by conducting joint scientific advice for regulatory and reimbursement bodies 
to optimise the study design; and conduct studies that enable data collection that jointly 
satisfy the requirements of regulatory and reimbursement bodies. Secondly, to improve 
existing methods for collecting and incorporating clinical and economic data to address the 
complexities associated with medical devices. Thirdly, identify the factors driving the 
diffusion of medical devices (Tarricone R, 2014). Thus, the recommendations from Medtech 
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HTA project could address the challenges encountered in the HTA of medical devices, 
however, there is still a strong need to understand and address the challenges encountered 
in the economic evaluation of medical devices.     
 
2.5. Challenges encountered in the economic evaluation of devices 
 
2.5.1. Feasibility of conducting clinical trials  
 
Device industries are highly innovative and continuously changing, with mostly small and 
medium sized manufacturers, and a few large companies. The implications of having to 
perform a clinical trial program could have a substantial financial impact on small and 
medium sized companies. Moreover, data from observational studies are commonly used 
for regulatory approval in the EU, as randomised controlled trials (RCTs) are not mandatory 
for EU approval. Therefore, the minimal evidence required for a regulatory approval makes 
it less encouraging for manufacturers to run a clinical trial programme. Unlike the 
pharmaceutical industry, lack of patent protection and the short lifecycle of medical 
devices discourages manufacturers from conducting additional research for market access 
and are only incentivised to conduct adequate research required for pre-marketing and 
post-marketing surveillance.  
2.5.2. Lack of comparator evidence 
 
Randomising patients to intervention or control groups permits balancing for unknown or 
unmeasured covariates i.e. demographic variables, severity of disease condition and 
professional use/preference bias. However, randomising patients to a comparative clinical 
trial might not be always feasible for the following reasons: i) ethical issues with 
recommending subjects to sham procedures; ii) denying patient access to the most 
appropriate treatment; iii) the design of the device could impose difficulty to randomly 
assign subjects to intervention/control group; iv) repeating clinical trials for every design 
modification might be challenging; v) and identifying the right comparator and recruiting 
the required sample size could be problematic with clinical practice varying from centre to 
centre. Therefore, medical devices commonly use observational study design for the 
comparison of safety and effectiveness of devices.  
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2.5.3. Issues around generating good quality and quantity evidence  
 
HTA of medical devices is hugely dependent on good quality evidence on clinical and 
economic effectiveness, and safety of the concerned device. The drug approval process 
requires appropriate, adequate and reliable evidence for marketing authorisation. 
However, such stringent pre-requisite of appropriate evidences are not mandatory for 
devices.  
 
o Confounding and blinding  
 
In the case of implantable medical devices, where the device is compared to medical 
therapy, it could be difficult to blind the subject and the investigator to the assigned 
intervention. In these situations, there could be no means of controlling for known and 
unknown variations across the groups, leading to inaccurate conclusions on device safety 
and effectiveness. The value of medical device is determined by the patient outcome and 
this outcome is directly related to the device performance and clinician contribution in 
implanting this device. Therefore, a superior outcome of a device is a culmination of device 
performance, surgical technique and operational efficiency of the device. Hence, it is 
important to adjust for any bias in user characteristics i.e. surgical technique, clinician skills 
and any learning curve effects on the study outcomes.  
 
The treatment effect estimated using observational studies are subject to treatment – 
selection bias in which the treatment group could differ substantially from the control 
group. Several traditional adjustment methods (i.e. matching, stratification and covariate 
adjustment) has several limitations and propensity score matching is considered  to be the 
most widely used method for bias reduction in comparison of a treatment to a non –
randomised control group. Propensity score is defined as the probability of treatment 
assignment conditional on measured baseline covariates; and the treatment status is 
independent of measured baseline covariates (Rosenbaum PR, 1983). The three most 
common techniques of propensity score are matching, sub-classification and regression 
adjustment (D’Agostino, 1998).  
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o Limitations in device class and its effect 
 
A drug class is defined as “the class of compounds which share a similar structure and 
mechanism of action. As a result of their similar mechanisms of action, drugs of a particular 
class produce similar pharmacologic effects and clinical outcomes (“class effects”)” (Soares 
I, 2002). This definition could also apply for devices in which evidence from studies using 
one or more devices within a class is assumed to be the same as other devices of the same 
class. For example, THR can be classified by their fixation method, implant components and 
femoral head sizes (Clarke A P.-J. R., 2015). The DePuy Articular Surface Replacement (ASR), 
a Metal–on–Metal Hip Implant consists of ASR Acetabular Cup System (manufactured by 
DePuy Orthopaedics); Metal Transcend Articulation System (manufactured by Wright 
Medical Technology); and Ultima Unipolar Head and Adapter Sleeves (manufactured by 
Johnson & Johnson Professionals) (Ardaugh M B, 2013). Out of three components, two are 
manufactured by different companies, showing that a hip prosthesis is a unique 
combination of different components manufactured by different companies, and the 
device performance depends on one or more components across manufacturers. 
Therefore, to accept a priori that clinical outcomes noticed within a class could be 
extrapolated to other THR implants would not be a reasonable assumption to make. This 
could also infer to other devices, therefore, it is important to compare the clinical and cost-
effectiveness of devices within and between device classes.  
 
o Less mature HRQoL data 
 
HRQoL is a standardised patient reported outcome measure used to assess the impact of 
the treatment on patient’s quality of life (Weinstein MC, 2009). EQ-5D is the most 
preferred measure to calculate QALYs and is the outcome measure recommended by NICE 
for economic evaluation. However, EQ-5D may not always be reported and in such a 
situation mapping can be used to predict utilities for each health states using data from 
other health measures i.e. mapping of NYHA to predict EQ-5D utility values (Longworth L, 
2011). Nevertheless, HRQoL measurements are not stipulated by regulators and 
reimbursement bodies, leading to its limited diffusion in research and decision making of 
 20 
 
 
 
medical devices. Technologies appraised through the MTEP committee use a CCA and do 
not require QALY as a measure to assess device outcomes (NICE, 2011). Lack of a 
standardised approach to compare treatment benefits across different health-care 
programs prevents to establish whether the device represents an efficient allocation of 
resources within the NHS setting, thereby a major limitation.  
 
o Inconsistencies in pricing 
 
Medical devices are procured through different methods and they include: procurement by 
trusts independently; centralised procurement processes i.e. the NHS supply chain; and 
NHS collaborative procurement hubs established in some NHS regions. Each NHS trust has 
also formulated its own procedure to procure devices in accordance with their respective 
trust contract regulations (NHS Foundation Trust, 2014). Likewise, devices could also be 
procured and delivered centrally by the NHS Supply chain, which is owned and managed by 
the Department of Health, and offers effective procurement practices. To summarise, the 
model and approach to procure devices varies by trust and region, and there is no 
consistency in device price across the NHS (Department of Health, 2011).  
o Absence of mature clinical data on treatment benefit  
 
 Time to event analysis are commonly used in economic evaluation to model the impact of 
treatment benefit and to define the treatment related health state. Survival modelling 
approaches most widely used in economic evaluations are restricted means analysis, 
proportional hazard modelling and parametric modelling.  The restricted means analysis 
and proportional hazard model is only used when there is relatively little censoring in the 
survival data and when the extrapolation is only based upon the observed data. Censored 
data are one form of missing data, where patients are either lost to follow-up or might not 
experience the event of interest before the end of the trial. Therefore, the censored data 
prevents a simple estimate of mean survival from the trial outcome. However, clinical trial 
data are often censored and the final outcome of interest is not observed for the 
randomised population. Hence, in the presence of censoring it is unlikely to estimate mean 
survival based on trial data alone, therefore, parametric survival analysis is greatly favoured 
in economic evaluation because the model estimates the baseline hazard function, thus 
 21 
 
 
 
drawing information from the whole data and dealing with issues of data censoring.  
Different parametric models can be used to extrapolate survival/time-to-event data to 
estimate transition probabilities for economic models. The most commonly used 
parametric models in economic evaluation are exponential, Weibull and Gompertz models.  
 
Parametric model  
Parametric models are models were a specific probability distribution is assumed for the 
survival function using the K-M estimate. For the economic analysis, several parametric 
models are fitted to the observed data and the model extrapolated based on the different 
modelled hazard function. For example, the observed data is shown in figure 1 and 
exponential fit to observed data is shown in figure 2.  
 
Figure 1 Illustrates observed survival and 95% CI while supported on a VAD 
 
Figure 2 Exponential fits to observed data month 3 and from month 3 to 23 while supported by a VAD 
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An example of the different modelled hazard are described in table 1 and shown in figure 3.   
Table 1 The parametric models 
Modelled hazard Description  
Exponential distribution The exponential distribution is the simplest 
parametric model for survival data because 
it assumes the hazard function is constant 
over time.  
Weibull distribution  
 
The Weibull distribution is more flexible 
than an exponential distribution, as the 
hazard function can either increase or 
decrease over time.  
 
Gompertz The Gompertz proportional hazard model 
is the most widely used model for human 
mortality. 
Accelerated failure time (AFT) model  AFT model can be used when the hazard 
function changes direction, and allows us 
to measure the direct effect of an 
explanatory variable on the survival time.  
 
Log normal distribution  
 
The log normal distribution is an 
accelerated failure time model and has a 
hazard function which can be non-
monotonic with time.  
 
Bath-tub model  
 
The failure rate function in a Bath tub 
model is characterised by a U- shaped 
curve comprised of three stages; an initial 
stage with a decreasing hazard function, a 
middle stage with a constant hazard 
function and a final stage with an 
increasing hazard function.  
 
Flexible parametric model 
 
A flexible parametric model using 
restricted cubic splines offers greater 
flexibility to model the baseline hazard 
compared to standard parametric models.  
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Figure 3 a) Bathtub model b) log-normal model c) log-logistic model d) Gompertz model e) Weibull model from 
Clarke A et al 2015 
The NICE technical support document on survival analysis recommends using parametric 
models to extrapolate data in health technology assessment (Latimer, N, 2011). In keeping 
with the NICE methods guide, it is important to assess the suitability of the survival model, 
the goodness of fit to the observed data, and the clinical and biological plausibility of the 
extrapolated data. The NICE Decision support unit (DSU) provides guidance on the model 
selection process, and have formulated a Survival Model Selection for Economic Evaluation 
Process chart to demonstrate the logical process needed to select a preferred model. 
However, in some instances the NICE reference case/DSU document would not seem 
applicable to all health technology assessment, where high-quality evidence is a challenge 
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to health economists, as seen with medical devices. Nevertheless, it is important to 
demonstrate that a logical and clear process was followed to select the preferred survival 
model, and the impact of model choice on cost-effectiveness results. The choice of a 
survival model could considerably vary the ICER, and therefore the decision to whether 
accept or reject the technology by the decision maker.  
 
In summary, the challenges encountered in economic evaluation of medical devices are: 
 Lack of appropriate comparators for the intended subject population 
 Issues around generating good quality and quantity evidence due to 
o Limitations in device class and its effects 
o Confounding and blinding 
o Less mature HRQoL data 
o Inconsistencies in pricing 
o Absence of mature clinical data on treatment benefit  
 
  
 25 
 
 
 
3. Rationale for this study  
 
This thesis explores the challenges described in the previous section using two specific 
devices – hip replacement prostheses and left ventricular assist device.   
 
3.1. Hip replacement prostheses  
 
People with hip problems due to osteoarthritis are surgically treated with a THR or RS. Both 
these procedures involve replacing the hip joint with a synthetic body part called a hip 
prosthesis, which consist of a femoral stem, head and acetabular cup made from different 
materials (i.e. metal, ceramic or polyethylene); and these implant components are fixed 
permanently to the pelvis and femur using different fixation methods (i.e. cemented, 
cementless, hybrid or reverse hybrid prostheses) (Clarke A, 2015). Therefore, based on 
different fixation methods for the femoral stem and acetabular cup in THR, they are further 
classified into cemented, cementless, hybrid and reverse hybrid THR (See figure 1).  
 
Figure 4 Different THR fixation methods (a) cemented THR (b) cementless THR (c) reverse hybrid THR (d) hybrid 
THR from Clarke A et al 2015 
 
Based on the frequency of use, combination of bearing and articulation surface; and 
method of fixation, the THR can be also characterised into five frequently used categories 
(see table 1) (Clarke A, 2015). 
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Table 2 Summary of THR prosthesis by five frequently used categories 
Device type Components 
A (CeMoP) Metal head (cemented stem) on Cemented polyethylene cup 
B (CeLMoP) Metal head (cementless stem) on Cementless hydroxyapetite coated 
metal cup (polyethylene liner)  
C (CeLCoC) Ceramic head (cementless stem) on Cementless hydroxyapetite coated 
metal cup (ceramic liner) 
D (HyMoP) Hybrid Metal head (cemented stem) on cementless hydroxyapetite 
coated metal cup (polyethylene liner) 
E (CeCoP) Ceramic head (cemented stem) on Cemented polyethylene cup 
 
3.1.1. Hip resurfacing (RS)  
 
Hip resurfacing is an alternative surgical technique to THR, mostly advocated for younger, 
active male patients with osteoarthritis (see figure 2) (NICE, 2000).  
 
 
 
Figure 5 Hip resurfacing from Clarke A et al 2015 
 
3.2. Left ventricular assist device (LVAD)  
 
LVAD is a mechanical circulatory device used to pump blood from the left ventricle to the 
rest of the body in patients with heart failure waiting for HT. This device is further classified 
into first, second and third generation LVADs (see figure 3); first generation LVADs consist 
of a pulsatile volume displacement device to pump blood; second and third generation 
device use magnetic continuous flow rotary pump. (Sutcliffe P, 2013) For the purpose of 
this thesis, the focus would be on CE approved second and third generation LVADs.  
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Figure 6 Types of LVADs from Sutcliffe P et al 2013 
 
Against this background, we describe the key challenges faced in the economic evaluation 
of devices and present the causes of these challenges in Table 2.  
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Table 3 Challenges encountered in the economic evaluation of devices: Application to hip replacement prosthesis and left ventricular assist device  
Challenges Description Causes 
Lack of comparator evidence  
Feasibility of conducting clinical trial  
No appropriate control for the 
intended subject population 
 
Standard of care for :  
 Patients with advanced heart 
failure - MM with inotrope 
 Patients with osteoarthritis - 
medical management, 
weight control and exercise. 
 Control group did not represent the subject population. 
 Historical control did not reflect current standard of care. 
 It was considered unethical to randomise subjects to intervention 
(VAD/Hip) because- 
 It would be challenging to recruit subjects to receive medical 
management, when VAD/Hip device group were expected to 
receive a benefit.  
 Extent of subject knowledge on VAD/Hip prosthesis for subjects 
awaiting surgery could be perceived to be denying treatment to 
control group subjects. 
Randomised clinical trial design is 
not mandatory to obtain market 
approval. 
 Manufacturers of these devices have less incentive to conduct a 
reasonably powered RCTs, as it is not a mandatory requirement for 
pre or post–market assessment. 
Issues around generating good quality and quantity evidence 
Limitations in device class and its 
effect 
Recommendation of devices based 
on class effect could be flawed.  
 Technology advancements  
 Improvements in clinical management of patients over time  
 Second and third generation VADs showed important differences in 
the mechanism of action, though approved for the same clinical 
indication. Similar difference was also noticed in hip prosthesis.  
Confounding and blinding Difficulty to blind devices due to 
difference in design and procedure 
 Both VADs and Hip prosthesis were compared to medical 
management; therefore, it was difficult to blind the subject and the 
investigator.  
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 Surgical technique, clinician skills and any learning curve effects 
could act as a confounding variable and pose challenges.  
 Person’s behaviour on hip prosthesis will affect the device 
performance i.e. patients physical activity could lead to friction and 
wear out the prosthesis. 
Less mature HRQoL data  Immature HRQoL data to support 
device outcome.  
 HRQoL data not mandatory to support reimbursement  
 Lack of QoL from RCTs 
Inconsistencies in pricing There is no centralised procurement 
process for devices and price paid for 
the same device could differ across 
different NHS trusts.  
 VADS and Hip prostheses are not procured centrally; therefore, 
devices are purchased through different processes in different NHS 
hospitals. Thus, the cost of the same device differs across centres, 
where special rebates and confidential volume based discounts are 
negotiated and offered, thereby reducing the generalisability of 
device cost.  
Absence of mature clinical data on 
treatment benefit 
Lack of long term data on median 
survival after VAD, MM with 
inotrope and HT. 
 The BTDB had missing values for some of the patients.  
 The database had no information about patients prior to VAD 
implantation.  
 There were no report of adverse events based on the type of VAD 
device.  
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3.3. Aim 
 
This thesis aims to identify and assess the most credible way of conducting economic 
evaluation when faced with the challenges mentioned earlier, using hip replacement 
prosthesis and left ventricular assist devices as examples.  
3.4. Objectives 
 
 To determine and describe the challenges encountered in the economic evaluation 
of medical devices. 
 To describe methods for robust economic evaluation of devices. 
3.5. Methods 
 
3.5.1. Data sources 
 
This research used the BTDB, which holds IPD from the six designated British centres 
responsible for VAD implantation and heart transplant. The database, overseen by the 
British Cardiothoracic Transplant Audit Group, holds the medical histories of patients with 
advanced heart failure on the waiting list for HT; and recipients of VAD implants and HT 
between May 2002 and December 2011.  
Likewise, this research also used IPD from the NJR for England and Wales for patients with 
osteoarthritis undergoing THR and resurfacing between April 2003 and December 2012.  
3.5.2. Analysis  
 
The economic evaluation for each type of device (LVADs and THR/RS) used a Markov multi-
state model to assess the cost-effectiveness of the device. For these models, three sets of 
model inputs were used: transition probabilities, costs and quality of life (utilities) 
associated with each health state. Transition probabilities between health states were 
modelled using KM time-to-event analyses with extrapolation beyond the observed data. 
Health outcomes were measured in QALYs and NHS and PSS resource use and costs were 
used.  
 31 
 
 
 
3.5.3. Main outcomes 
 
o Observed and modelled survival  
 
BTDB patient level data was used to model time to death on VAD support and MM, time to 
heart transplant and cumulative incidences of HT.  
NJR data was used to model lifetime revision for men and women with THR and RS.  
o Other main outcomes 
 
Lifetime costs, lifetime QALYS and the probability of a device being cost-effective at the 
NICE WTP threshold.  
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4. Summary of the published work  
 
The overall aim of this thesis is addressed using four publications, and the body of research 
are linked to each other as shown in figure 4. First, we published a cost-effectiveness 
analysis of LVADs for patients with advanced heart failure, based on a Markov model. A 
second publication compared the cost-effectiveness of third generation VAD (i.e. HW) 
versus second generation VAD (i.e. HMII). The above two publications were used to address 
the challenges encountered in economic evaluation of VAD devices. In the next two 
publications, we used a Markov model to explore the cost-effectiveness of five frequently 
used categories of THR; and cost-effectiveness of metal-on-metal resurfacing versus THR in 
patients with osteoarthritis. 
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Credible ways of performing economic evaluation of medical devices 
Covariate adjustment 
by age & sex 
Figure 7 Logical representation of the publications used to illustrate credible ways of performing economic evaluation of medical devices 
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4.1. Study 1- Cost-effectiveness of left ventricular assist devices (LVADs) for patients 
with advanced heart failure: Analysis of the NHS bridge to transplant (BTT) program 
(Clarke, 2014). 
 
 Introduction 
 
LVADs are an implantable mechanical device used as a BTT for patients with advanced 
heart failure. Based on the specific characteristics of the device, LVADs are further 
classified into first, second and third generation devices. In 2002, the NHS BTT program 
was formed to support VAD therapy in the UK. The clinical and cost-effectiveness analysis 
of first generation LVADs showed them not to be cost-effective at NICE WTP threshold.  
 
Objective 
To investigate the cost-effectiveness of second and third generation LVADs as a BTT, 
compared to MM with inotrope support in the NHS BTT program. 
 
Methods  
Clinical outcomes 
The BTDB contains individual patient medical history for all advanced heart failure patients 
on the waiting list for HT; LVAD patients; and HT patients. All patients who received a 
second or third generation LVAD between May 2002 and December 2011 as a BTT, bridge 
to decision for HT, or bridge to myocardial recovery were included in this analysis. 
Parametric models were used to extrapolate beyond the observed data.  
 
Economic model 
A semi-Markov multistate structure was built in which each patient exists in one of three 
mutually exclusive health states: alive on LVAD or MM support; alive after HT; dead - the 
absorbing health state. Individual patient data (IPD) was used for KM time-to-event 
analyses to estimate the transition probabilities for recipients of LVAD implants as BTT, 
recipients of heart transplants and all patients on MM for advanced heart failure. The 
model was run for a lifetime horizon (50 years), and shorter time horizons of 3 and 10 years 
were explored in sensitivity analyses. Probabilistic sensitivity analysis was undertaken to 
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account for uncertainty in individual patient outcomes and parameter uncertainty. The 
costs and benefits were evaluated from the UK NHS perspective. An annual discount rate of 
3.5% was applied to costs and beneﬁts.  
Health outcomes 
We used the New York Heart Association (NYHA) patient level data from BTDB to obtain 
EQ-5D utility scores.  
 
Cost estimates 
The device cost for second and third generation LVADs were obtained from six NHS 
hospitals responsible for implementation of BTT program. LVAD implant, heart transplant 
procedure and post-operative support costs were based on a previous analysis and inflated 
to current prices by applying the projected Health Service Cost Index (PSSRU, 2010).  
Results 
Clinical outcome 
235 patients were registered on the database as having had a second- or third- generation 
device. Amongst these, 125 received HW, 82 HMII, 23 Jarvik 2000 FlowMaker, and 5 
Micromed Heart Assist devices, respectively. At 2 months, survival was apparently similar 
for patients receiving an LVAD compared to those receiving MM with inotropes (LVAD 89% 
vs. MM 83%). Modelled survival and time to transplant varied considerably for patients on 
MM with inotropes relative to patients supported with an LVAD. Survival with a transplant 
was good, with over 75% survival at 24 months. 
Economic analysis 
The ICERs for the 3 year, 10 year and lifetime time horizons were £120,510/QALY (95% CI: 
£79,560 to £251,285), £67,119/QALY (95% CI: £38,756 to £116,681) and £53,527/QALY 
(95% CI: £31,802 to £94,853) respectively. According to the current UK threshold of 
£20,000 to £30,000/QALY recommended by NICE, LVADs cannot be considered to be cost-
effective. At a higher WTP threshold of £50,000 /QALY (end of life criteria), the probability 
that LVADs are cost-effective is 0%, 13.3% and 40.7%, over the 3 year, 10 year and lifetime 
horizons respectively. 
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4.2.  Study II- Comparative cost-effectiveness of HeartWare versus HeartMate II left 
ventricular assist devices used in the United Kingdom National Health Service 
bridge to transplant program for patients with heart failure (Pulikottil-Jacob, 2014).  
 
Introduction 
HMII (HMII, Thoratec, Pleasanton, CA) and HW (HW, HeartWare International, 
Framingham, MA) are the two most frequently used LVADs in the UK. HMII is a second 
generation magnetic continuous flow rotary pump implanted below the diaphragm in the 
abdomen. HW is a third generation LVAD with a small centrifugal pump implanted in the 
pericardial space. The clinical benefits and risks of LVAD implantation has been extensively 
studied, however, there have been no comparative studies between the two devices. 
Therefore, it is important to evaluate the clinical and cost-effectiveness of these devices to 
support the right choice for the indicated population.  
Objective  
To investigate the clinical outcomes for individuals implanted with HMII and HW devices in 
the UK; and to estimate the cost-effectiveness of the HW compared to the HMII for 
patients treated in the UK NHS BTT program.  
Methods 
Clinical outcomes 
All patients who received an HW or HMII as a BTT, bridge to decision for HT, or bridge to 
myocardial recovery between May 2002 and December 2011 were included in this analysis. 
Principal outcomes recorded in the BTDB after implantation of an LVAD were HT, 
explantation of the device, remaining alive with the originally implanted device, and death 
while supported with the originally implanted device. These outcomes were investigated 
with KM time-to-event analyses and with cumulative incidence methodology for competing 
outcomes.  
Economic model  
A semi-Markov multistate structure was built using Excel. Each patient in the model exists in 
1 of 3 mutually exclusive health states: alive on LVAD; alive after HT; dead. IPD was used for 
KM time-to-event analyses to estimate the transition probabilities for death amongst those 
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who received a LVAD or an HT, and time to HT. Parametric models were used to extrapolate 
beyond the observed data. 
 
Health outcomes 
NYHA classification of patients in BTDB was used to determine EQ-5D utility scores.  
 
Cost estimates 
The mean cost for the HW was £80,076 and ranged from £76,774 to £98,160; the mean cost 
for HMII was £89,830 and ranged from £78,877 to £126,702.  
 
Results 
Clinical outcomes 
Observed survival was superior for the HW recipients (63%) compared with HMII (40%) at 
750 days. According to KM analysis at 6 months, there was little difference in survival 
between groups. By 12 months, an estimated 24% of HW patients and 34% of HMII 
recipients had died.  
 
Economic analysis 
The economic analysis found individuals who received HW incurred more costs but 
accrued more life-years and QALYs than did HMII recipients. The base-case probabilistic 
analysis indicates that implanting HW compared with HMII would cost the NHS on average 
an additional £24,379 over the lifetime of an individual (95% CI, dominates to £108,940), 
with an ICER of £20,799 per QALY gained (95% CI, dominant to £79,837).   
  
 38 
 
 
 
 
4.3. Study III- Cost-effectiveness of total hip arthroplasty in osteoarthritis: a comparison 
of devices with differing bearing surfaces and modes of fixation (Pulikottil-Jacob R, 
2015)  
 
Introduction 
THR is a commonly undertaken procedure, and with increasing demand for THR more 
attention is being paid to its cost-effectiveness and the choice between designs and modes 
of fixation. For osteoarthritis, more than 80,000 surgeries are performed each year in the 
UK, and over 100 different brands of prosthesis are available, manufactured by at least 20 
companies with varying performance and cost. It is worth noting that each brand has 
individual purchasing arrangements with orthopaedic centres, rather than a NHS wide 
procurement. Hence, identification of the most cost-effective device would allow 
significant cost savings for the NHS.  
Objective 
To examine and compare the cost-effectiveness of frequently used combinations of 
components in THR, including the type of fixation and bearing surfaces. 
Methods 
Clinical outcomes 
Patients undergoing THR for osteoarthritis between April 2003 and December 2012 were 
selected from the NJR for England and Wales. The registry provided IPD of hip prosthesis 
and combinations of components by usage. This study focussed on the most commonly 
used components by stratifying the various combinations of components using an iterative 
cross-tabulation procedure. This procedure selected four combinations based on the 
highest recorded usage, and one additional combination was added based on expert 
opinion. KM analysis was used to estimate time to revision for the above five prosthesis 
combinations. NJR data was stratified by sex and controlled for age. Parametric 
distributions were fitted to KM data and models extrapolated to a lifetime horizon.  
 
Economic model 
A multi-state Markov model was built to model the cost-effectiveness of each THR 
combination. In this model, patients exist in one of four mutually exclusive states: successful 
primary THR; revision surgery (patients can move into this state more than once but stay in 
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this state for one annual cycle only); successful revision surgery; death (patients may enter 
this state both due to operative mortality or due to death from other causes). Model inputs 
were yearly transition probabilities of converting from successful THR to revision surgery or 
death; costs associated with different prostheses, hospital costs and follow–up costs.  
 
Health outcomes 
Quality of life data were obtained from Patient reported outcome measures (PROMs) 
database for patients who had a THR from January 2009 to December 2012. EQ-5D data 
were available for patients post successful THR and revision THR by age and sex.  
Cost estimates 
Costs of prostheses were obtained from NHS supply chain and mean cost of each 
prosthesis was estimated using list price from the most commonly used suppliers.  
Results 
The NJR included records of 386,556 patients with osteoarthritis, and 62% of osteoarthritis 
patients accounted for five frequently-used combinations of prosthesis (239,089 records). 
The overall rates of revision were higher in men than women. The distribution of age 
varied between categories, but was similar for men and women within each category. In 
all categories, apart from category CeCoP, the difference in rates by sex was statistically 
significant (p<0.05) both with and without stratification for age. Revision rates for the 
lifetime model were lowest for category CeCoP and highest for category CeLCoC, 
irrespective of sex and age.  
 
Economic analysis 
The base-case results for men and women aged 60, 70 and 80 years showed marginal 
differences in costs and QALYs between the five different types of prosthesis. Although, we 
used alternative cost and QoL inputs in a sensitivity analysis, the difference in cost-
effectiveness between different types of prosthesis were minimal.  
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4.4. Study IV- Has metal on metal resurfacing been a cost-effective intervention for 
health care providers? - A registry based study (Pulikottil-Jacob R, 2016)  
 
Introduction 
RS accounted for about 7.5% of UK implants in 2007, but due to poor revision performance 
and concerns about metal debris, the use of RS had declined in 2012 to only about a 1% 
share of UK hip procedures. Currently, some still advocate RS for young and active men 
with large femoral head size. The NICE guidance for hip replacement recommends a 10 
year revision rate benchmark of <5%. Like THR devices, RS devices produced by different 
manufacturers differ with respect to revision rate, and currently RS devices from sixteen 
different manufacturers have been used in the UK. Therefore, it is worth exploring whether 
implantation of any RS devices or the best RS devices in highly selected patients such as 
active young men with large femoral head size could be considered cost-effective.  
Objective 
To assess the cost-effectiveness of RS versus THR in device-patient combinations likely to 
satisfy the NICE benchmark of less than 5% revisions at 10 years.  
Methods 
Clinical outcomes 
The NJR for England and Wales supplied IPD for RS and THR surgery for osteoarthritis 
recorded from April 2003 to December 2012. A flexible parametric modelling method was 
used to identify combinations of patients and devices that had satisfied the NICE 
benchmark. Data were stratified according to sex and pooled by device manufacturer and 
patient subgroups. All THR devices have shown revision rates within the NICE benchmark, 
hence, the five most frequently used THR devices were selected for comparison with RS on 
the basis of frequency of use of components.  
Economic model 
A multi-state Markov model was built to model the cost-effectiveness of the most used 
THR for comparison with RS. Model inputs were yearly transition probabilities for time to 
revision and to death, costs, and utilities of health states. The age-related utilities were 
assumed to be the same for the comparison of RS with THR.  
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Results 
Clinical outcomes  
KM analyses indicated that for all six manufacturers, men experienced lower revision rates 
than women. Flexible parametric models predicted a low probability of satisfying the 10 
year NICE benchmark. The only device delivering an overall revision rate within or near the 
10 year benchmark was the Birmingham Hip. For women, no manufacturer’s device 
delivered a revision rate within the benchmark. All exceeded 5% revision within only 5 
years, and by 10 years, predicted rates in women were all greater than 10%. For men the 
revision rate was poor for most manufacturers and flexible parametric models predicted a 
low probability of satisfying the 10 year NICE benchmark.  
 
Economic analysis 
For the base-case economic analysis we compared the most used RS (Birmingham hip, 
within NICE benchmark) with the most used THR device (CeMoP) in male grade ASA 1 plus 
ASA grade 2 patients. This analysis indicated that Birmingham Hip accumulated fewer 
lifetime QALYs for 40, 50 and 60 year old men, lifetime costs were greater for RS by at least 
£2,900 and RS was dominated by THR for 60 year old men, and the probability that RS was 
cost-effective remained low (<4%) compared to THR at a WTP of £20,000/QALY. The 
probability that RS was cost-effective was < 6% at a WTP of £20,000/QALY for the Biomet 
RS and Finsbury devices when compared with the best performing THR device (CeCoP) in 
male grade ASA 1 plus ASA grade 2 patients.   
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5. Discussion  
 
This thesis tries to address the several challenges encountered in the economic evaluation 
of medical devices and ways to deal with these challenges. This enables estimates of cost-
effectiveness to be derived in situations where sufficient comparative data, utility and cost 
data are lacking to do standard economic evaluation. However, the challenges discussed 
here are not exclusive to devices and could be applicable to both drugs and devices, due to 
certain overlaps noticed and accepted across both the groups.  
 
5.1. Lack of comparator evidence  
 
Lack of comparator evidence is a major challenge in the assessment of clinical and cost-
effectiveness of devices. We propose constructing an artificial “control arm” to overcome 
this challenge. The survival estimates for the control arm were explored using the 
application of the Seattle Heart Failure Model (SHFM) to the baseline characteristics of the 
intervention group (constructing an artificial “control arm”) (Levy WC, 2006). This artificial 
control arm could be used to attain the statistical impact of a two-armed randomised trial. 
Therefore, in our analysis, we constructed an artificial MM using patient characteristics of 
VAD patients, so VAD patients could act as their own control. We acknowledge that this 
approach has its own limitations, but in absence of an appropriate comparator this forms 
the best approach we could use to test the robustness of patient selection in the economic 
analysis. However, similar method have been used in the past to draw causal inferences 
from the study of a treatment or intervention in an event of a lack of an experimental 
design (Schaffer et al, 2009). This study concluded that SHFM scores most accurately 
predicted survival on MM and could be used to identify patients who might benefit from 
LVAD implant (Schaffer JM, 2009). Likewise, Aaronson et al developed a predictive model 
(i.e. the heart failure survival score) to accurately identify individuals with advanced heart 
failure and most likely to require urgent transplantation (Aaronson KD, 1997).  However, 
comparison with artificial controls can yield biased results due to sampling bias.  
Nonetheless, we undertook extensive sensitivity analysis to test the uncertainty associated 
with our comparator group. 
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Firstly, we sort expert opinion, and clinical advisors asserted that the median survival 
observed in real life was close to survival observed for MM patients in the REMATCH trial. 
The REMATCH trial (Rose EA, 2001) was the only multicentre RCT study for patients with 
end-stage heart failure who received VAD as long-term circulatory support. Therefore, in 
view of a possible overestimate of survival for the BTDB inotrope control group, the MM 
group from the REMATCH trial (Stevenson LW, 2004) was explored as a control group in a 
sensitivity analysis. 75% of patients in the REMATCH trial (Stevenson LW, 2004) were 
treated with inotropes and was considered to be too unwell for HT with median survival of 
4.9 versus 9.1 months for the BTDB inotrope control group. Hence, the MM group from the 
REMATCH trial (Stevenson LW, 2004) was considered to be the optimum MM group due to 
older age and higher disease severity. This analysis showed that the ICER barely changed 
from the base-case results, therefore, revealing that the base-case ICER was reasonably 
robust. The reason for this is that even though the poorer survival of the MM arm results in 
an increase in the difference in QALYs between BTT and MM, this poorer survival also 
results in lower costs in the MM group. Thus, an increase in the difference in costs between 
BTT and MM tend to cancel out the difference in QALYs when calculating the ICER.  
Secondly, we identified appropriate comparators based on their clinical relevance and 
granularity of the prosthesis. This iterative process enabled us to categorise the five most 
frequently used THR prostheses for patients with osteoarthritis. However, publication by 
Pennington et al (Pennington M, 2013) compared three types of prosthesis i.e. cemented, 
cementless and hybrid prostheses for THR and reported that hybrid prostheses was the 
most cost-effective device. Our results varied from the published evidence and showed 
that the lifetime rates of revision were lowest for CeCoP and highest for category CeLCoC. 
This difference in result could be due to the difference in methodology used to examine the 
types of prosthesis, as Pennington et al (Pennington M, 2013) did not examine the 
differences in the bearing surface. 
Finally, we used propensity score matching technique and covariate adjustment to address 
biases encountered in the economic evaluation of medical devices for the following reason-
RS implants are widely perceived to be suitable for younger active patients (Pollard TC, 
2006). There is no long-term RCT data to validate this benefit; however, the age 
distribution of patients implanted with RS supported this perception i.e. NJR database 
showed that most RS patients were male (70%) with mean age of 55 years compared to 
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30% of THR male recipients with mean age of 61 years. We noticed observed difference in 
sex mix of THR and RS population; twice the proportion of women received THR than RS. 
The literature also indicated that the revision rate for RS was higher in women than in men. 
Hence, the difference in age and sex between RS and THR patients was a major limitation 
of our analysis, and the only viable option to adjust for this difference was to model THR 
revision rates outside of the observed age distribution i.e. controlled for age as a covariate. 
Therefore, we used propensity matching to stratify data according to age and sex; and 
compared devices by their manufacturer, femoral head size, patient ASA grade and age at 
the time of primary intervention. In this comparison our results indicate that RS is unlikely 
to be cost-effective compared to THR at a WTP of £20,000/QALY. Recent trends in clinical 
practice suggest that RS is becoming less popular among patients with severe arthritis of 
the hip.  
To summarise, in circumstances where head-to–head randomised comparison of devices 
are absent; artificial comparator, granular and clinical relevant classification of prosthesis, 
and sensitivity/scenario analysis assists to improve the credibility of the cost-effectiveness 
estimate.  
 
5.2. Limitations in device class and its effect 
 
Devices undergo constant modification from their initial form to overcome initial 
shortcomings. Therefore, there is a need to clearly distinguish between devices by 
class/generation. It could be clearly seen from our analysis that second and third 
generation LVADs have improved survival prospects in comparison to first generation 
devices. The difference between the second and third generation devices is that third 
generation device uses non-contact bearing also known as magnetic levitation (MAGLEV) 
which allows rotation without fiction or wear, whereas second generation devices use 
contact bearings. Therefore, it is broadly believed that third generation devices could 
reduce thrombotic events and improve durability (Rodriguez L, 2013). Although, the new 
technology has been widely used for the management of patients with end stage heart 
failure, but there have been no good quality randomised/non-randomised trials evaluating 
the benefits of second versus third generation LVADs (Girling AJ, 2007). The technology has 
not been fully evaluated using prospective studies, therefore, doubts do remain in the 
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technological advancement of third generation pumps (i.e. MAGLEV), if they could 
generate significant benefit.  
Our study ﬁndings support clinicians and decision makers to make more rationalised 
decision on which of the different LVADs to consider within the NHS-supported BTT 
program. Had we pooled the LVADs together with the aim of estimating cost-effectiveness 
relative to MM might have seriously mislead clinicians/decision makers to reject LVADs 
based on poor performance.  
The NJR dataset contained 387,667 records of THR and 31,222 patients’ records of RS. 
Comparing all THR and RS categories with each other would have been an impractical task 
to consider, therefore, we compared between five identified THR categories; and the best 
RS devices that satisfy the NICE benchmark (i.e. 5% revision rate at 10 years) versus five 
frequently used THR categories.  Our analysis clearly showed that the five THR categories 
differed in the observed revision rates. Ceramic head (cemented stem) on cemented 
polyethylene cup (CeCoP) had the lowest observed revision rate, however, the difference in 
cost and QALYs were minimal between the two categories.  
NICE technology appraisal (TA2) on the selection of prostheses for primary THR did not 
differentiate THRs based on their bearing surface and fixation, and recommended 
cemented prostheses for primary THR (NICE, 2000). Conversely, TA44 recommended 
metal–on–metal hip RS in June 2002 (NICE, 2002), however, in June 2012 MHRA issued 
medical alert for all metal-on-metal hip RS implants following concerns on the revision rate 
(MHRA, 2012). Identification and distinguishing devices across different RS prostheses by 
manufacturer and fixation method could have prevented recommending such devices for 
continued use.  
Therefore, in our study, we classify devices based on their granularity and clinical relevance 
and provide a clear indication of important differences across different categories of hip 
prostheses.  
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5.3. Absence of mature HRQoL and cost data 
 
The lack of individual patient level EQ-5D data to estimate QALYs could impede robust 
economic evaluation of LVADs. The BTDB did not provide EQ-5D data, therefore, we used 
HRQoL data from the literature. Two sources of EQ-5D utility scores were available from 
published literature (Sharples LD, 2006) (Gohler A, 2009), and the evidence from these 
literatures highlight a strong relationship between NYHA class and utility (i.e. NYHA class 
deterioration was associated with utility loss). Therefore, we used NYHA class recorded for 
patients at registration; 3 months post LVAD and heart transplant to estimate EQ-5D utility 
scores. Nonetheless, we also undertook univariate sensitivity analysis using utility scores 
from Sharples et al (Sharples LD, 2006); however, the ICER barely differed from the base-
case.  
Outcomes for the primary THR, RS and revision THR were modelled in QALYs. Utility data 
were obtained from the PROMS database, however, we were unable to link NJR and 
PROMS dataset by patient identifiers. In light of this limitation, we adjusted EQ-5D scores 
by age and sex to overcome population differences. Based on this approach, our analysis 
demonstrated slightly better utility scores for men than women. The base-case results for 
ten year and lifetime horizons for men and women aged 60, 70 and 80 years showed very 
small differences in accumulated QALYs between prosthesis categories. These small 
differences were driven by the disutility associated with revision. Although, we undertook 
extensive sensitivity analysis to test the robustness of the utility data, we acknowledge lack 
of mature HRQoL to be a major limitation in our study.   
The main source of cost inputs in our economic evaluation of BTT with LVADs compared to 
MM was from Sharples et al (Sharples LD, 2006). It is worth mentioning that the cost data 
reflected in the Sharples et al (Sharples LD, 2006) publication were based on a mixture of 
first and second generation LVAD devices. Although, our economic analysis were based on 
second and third generation devices; we still used resource use data from Sharples et al 
(Sharples LD, 2006), as it was the only cost data available from the NHS perspective. We 
obtained the cost of LVADs from five centres across the UK operating the BTT program. The 
centres with low number of LVAD usage showed greater purchase price in comparison to 
centres associated with a greater number of LVAD implants. Moreover, the cost towards 
device maintenance (i.e. replacing batteries, cables or any hardware associated with the 
 47 
 
 
 
device) was largely unclear, as some centres specified that the maintenance cost would be 
included in the purchase agreement; some centres reported the cost to be trivial; and two 
centres reported £4,000 per year towards cost of maintenance. Another limitation was lack 
of short and long-term cost data on adverse events; and evidence on requirement of LVAD 
replacement. All these model assumptions were explored in the sensitivity analysis. Our 
results indicate that the cost of the device was a key driver of cost-effectiveness, as a 15% 
reduction of device cost reduced the ICER threshold to £50,000 per QALY; and a substantial 
reduction in device price (i.e. 76%) was required to reduce the ICER to £30,000 per QALY. 
Our study ﬁndings support clinicians and decision makers to identify the maximum price 
they may be willing to accept for LVADs within the NHS-supported BTT program. 
Cost estimates of THR and RS prosthesis by type were obtained from two sources the NHS 
Supply Chain (June 2013) and from the respective manufacturers. These sources differed 
considerably, making it difficult to ascertain what would be the approximate price paid by 
NHS trust in reality. A price of prosthesis can vary from £800-£2150 per trust and there is a 
clear lack of transparency and consistency over pricing of prosthesis, as price paid by trusts 
vary considerably due to wide variation in discounts based on individual purchase 
agreements (National Audit Office, 2000). Report by the National Audit Office state that 
three quarters of trusts have negotiated a price discount for hip prosthesis based on the 
volume of purchase (National Audit Office, 2000). In 2014, NJR introduced the Economic–
model-and–price-benchmarking (EMBED) service to support NHS commissioners to reduce 
their orthopaedic implants spend without compromising on patient outcomes.  EMBED is 
expected to provide NHS trusts with an overview of their usage and total spend on hip 
prosthesis in comparison with other NHS trusts, as a means of cost-saving (National Joint 
Registry, 2014). However, even now (November 2016?) no such scheme is in place to 
support procurement of VAD implants across different NHS trusts.   
In 2016, NHS England launched the centralised supply chain for the procurement of high 
cost tariff excluded devices, and NHS Supply Chain was appointed to operate this newly 
centralised supply chain on behalf of NHS England (NHS England, 2016). Currently, this has 
been only rolled out to high cost tariff excluded devices, and one would anticipate similar 
services would be beneficial to address the inconsistency noticed over pricing of other 
devices i.e. devices included in the National Tariff Payment System. 
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5.4. Absence of mature clinical data on treatment benefit  
 
We applied time-to-event analysis to improve the robustness of the economic evaluation. 
Our base case analysis revealed that the ICER was critically dependent on the probability of 
receiving a heart transplant. Time to HT was very different between BTDB MM and BTT 
patients, as the median time to transplant in MM patients were 3.25 months compared to 
44.7 months for LVAD patients. Moreover, our clinical expert confirmed that MM patients 
are prioritised over LVAD for transplant when donor heart is available. Hence, time-to-
event analysis was used to model a high probability of receiving a HT for the MM group, 
than patients supported on LVAD. For the MM patients, the log-normal distribution 
provided the lowest AIC and the best fitting model, however, for the BTT patients, 
exponential distribution was the best fitting model. Therefore, the survival benefits were 
estimated using different possible model fits (i.e. log-normal fit to time to HT for MM 
patients; and exponential fit to time to HT for BTT patients) and extrapolated to predict 
long term survival. This analysis showed that inclusion of different model fits to the 
observed data changed the resulting cost-effectiveness estimate i.e. lifetime ICER for LVAD 
was considerably larger, and MM was more effective and less costly than BTT. Although, 
the DSU guidance for modelling time to event recommends to adopt the same parametric 
form for the intervention being compared, however, our results demonstrate that for 
observational data, parametric fits for different interventions groups may not be well 
described by a single parametric form (Latimer, N, 2011).  Thus, further research is needed 
to support the relaxation of this assumption.  
Likewise, study III highlights the application and effect of different parametric models on 
cost-effectiveness estimates. In the base case analysis, bath tub models were used to 
predict life time revision rates for 60, 70 and 80 year old patients. Bathtub models predict 
an initially decreasing hazard for revision (i.e. after primary surgery) followed by an 
increasing hazard as the prosthesis ages, and the quality of the patient’s bone deteriorates. 
We used a direct approach in which a single bath tub model was employed, whereas 
Pennington et al. 2013 combined two Weibull models (one for early and one for late THR 
failures) in order to achieve the bath tub hazard profile; this may have led to difficulties in 
extrapolation so that “capping” of revision rates was sometimes necessary. Therefore, the 
direct bathtub modelling avoids the problems seen in analyses of combining two separate 
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Weibull distributions. Lognormal models adjusted for patient’s age were used in sensitivity 
analyses to predict the revision rates to 100 years of age. With lognormal models the 
predicted revision rates were reduced, as were the magnitude of the differences between 
prostheses. However, the relative performance of prostheses was similar to that with the 
bath tub models. Therefore, we tested the extrapolation generated from well-fitting 
models predicting a gradual increase in the rate of revision with time (i.e. bathtub model) 
and models predicting a gradual decrease in rate of revision with time (i.e. log-normal 
model). The trajectory of revision rates using our predicted model was compared with the 
Swedish registry data (reported follow-up data up to 20 years) supported an increasing 
hazard, therefore, demonstrates the validity of our chosen model.  
To summarise, across four publications there were moderate differences in ICERs for the 
base case and the sensitivity analysis, however, all the analyses led to the same decision 
regarding the cost-effectiveness of these devices.  
5.5. Value of information analysis  
 
The uncertainty surrounding the cost-effectiveness of a LVAD was represented as a cost-
effectiveness acceptability curve (CEAC). The CEAC illustrated that the LVAD had a very low 
probability of being cost-effective i.e. less than 15% at NICE WTP threshold of £30K/QALY; 
and 25% at £50K/QALY (using NICE end of life criteria). Therefore, the decision to reject or 
adopt the device based on the existing information could be uncertain; and the cost of 
uncertainty was explored using value of information analysis (VOI).  The UK population 
expected value of perfect information (EVPI) was £670, 000 at £30K/QALY; and £13 million 
at £50K/QALY. However, the expected cost of conducting future research is more likely to 
exceed £700,000, due to the inherent cost of the required type of research; and the 
potential cost associated with the research (i.e. device cost, operative cost and treatment 
and follow-up visit). However, LVADs do tend to satisfy the NICE end of life criteria, where 
NICE tends to apply a threshold of £50K/QALY. At this threshold, the expected upper limit 
on the returns to further research is approximately £13 million (10 year life time). 
Therefore, for deciding to conduct more research, the expected value of sample 
information analysis would be worthwhile to fully inform the research design and the 
optimal sample size required to conduct further research. Likewise, EVPI analyses based on 
the evidence available from the REMATCH trial was explored by Girling et al (Girling et al, 
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2007), and the study concluded that a future trial was not expected to be cost-effective at 
the existing device cost (cost of the device was estimated to be £60,000). Indeed, the 
actual price of a device is a grey area and would continue to be so due to the competition 
within the market. Moreover, it would not be possible to examine the effectiveness of VAD 
alongside a clinical trial for ethical reasons, as randomising patients to a trial offering equal 
probability of HT for each group would not be workable.  
The CEAC for the comparison between different types of THR; and THR vs RS at NICE WTP 
threshold of £20K/QALY was greater than 95%. As THR has shown to be a cost-effective 
technology, it is unlikely to benefit from additional research.  
 
5.6. Study strengths 
 
The approaches described in this thesis are comprehensive, and it provides robust 
information that payers need to make decisions on the cost-effectiveness of these devices. 
Furthermore, the studies project the long-term clinical outcomes in a cohort of patients 
with implanted hip prostheses and LVAD devices, as well as a detailed cost-effectiveness 
estimates.  
 
A key strength of these studies is the use of real world evidence of hip prostheses and 
LVADs from the NJR and BTDB databases. BTDB provided key clinical characteristics for 
greater than 1000 individual patients receiving a relevant LVAD and MM over 9 year 
period. This study also used a virtual control to assess the choice of the comparator 
population. This approach was critical is testing the robustness of the cost-effectiveness 
estimate in absence of direct comparative evidence.  
 
Similarly, the NJR database provided good quality data on time to revision after primary 
THR for 386,556 patients with osteoarthritis spanning 10 years. Using the NJR dataset, we 
further identified five frequently used types of prosthesis, classified according to both 
bearing surface and mode of fixation. This approach increased the granularity and clinical 
relevance of this study. This is the first lifetime cost-effectiveness analysis comparing five 
frequently used types of THR prosthesis, and comparing THRs with RS in young active 
patients. The main strength of this study lies in the flexible parametric and direct bathtub 
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modelling used to predict revision rate. The bath tub model predicts an initial decreasing 
hazard for revision after primary surgery followed by an increasing hazard as the 
prosthesis ages and the quality of the patient’s bone deteriorates. This modelling 
approach avoided the problems seen in other publication where two separate Weibull 
distributions were combined to model revision.  
 
Another major strength of this work is the application of propensity score matching to 
reduce confounding, therefore, assisting in obtaining the most credible cost-effectiveness 
estimates for devices.  
 
5.7. Study limitations 
 
There are limitations in the economic evaluation approaches, for example all approaches 
listed in this thesis require collection of observational data to allow estimates of cost-
effectiveness. However, short and long-term clinical outcomes data are not routinely 
captured within an electronic health record data for patients with implanted devices. This 
may mean that the approaches illustrated in this thesis could only be used to assess the 
cost-effectiveness of medical devices, where there are existing clinical databases for post-
marketing devices.  
A major limitation of study I and II are, like all other studies on VAD devices, is around the 
nonrandomised comparison across devices. Therefore, the survival difference seen 
between the two devices could be due to external factors and not due to the difference in 
performance of the actual device. The length of follow-up of patients supported by either 
MM or a LVAD was short and no randomised or controlled evidence were available to 
inform the choice of an appropriate MM population to act as a comparator to BTT with a 
VAD. In addition, extrapolation beyond the observed data was required to model survival, 
and this unavoidably leads to bias regarding the estimation of transition probabilities in the 
longer term. The lack of short-term and long-term EQ-5D utility scores, and absence of 
reliable long-term EQ-5D data from published literature may be a possible limitation.  
The BTDB contained limited clinical variables for the patients in this dataset. Although, the 
NJR contains good individual patient data for time to revision after primary THR, some key 
data were still missing (i.e. patient level activity data, body mass index; and adverse 
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events). We acknowledge that the lack of randomisation may lead to unexplored 
confounding and that observational studies could be susceptible to bias due to the limited 
ability to adjust for hidden covariates (i.e. level of physical fitness and athleticism may 
dictate patient selection for RS versus THR). For the cost-effectiveness analysis, we sourced 
model inputs from several different sources and were unable to link the three data sources 
i.e. PROMS, hospital episode statistics and NJR using patient records. This approach could 
have provided a better cost and QoL estimate by prosthesis type.  
 
5.8. Study implications and recommendations 
 
The findings from our studies revealed that LVADs considered as a BTT yield ICERs of 
£55,173, when compared with MM. Although LVADs were not considered cost-effective at 
NICE’s standard WTP thresholds, they clearly demonstrated an improvement in QoL and 
functional status for patients who survive implantation of a LVAD as BTT. Our findings 
showed that patients on the HW device had superior survival than those on the HMII. 
However, it is clear that third generation LVADs are evolving and show a greater advantage 
over first and second generation LVADs. Therefore, LVADs clearly support survival benefits 
for BTT patients and a reduction in device costs would bring the ICER to the NICE WTP 
threshold. The cost of VAD would need to be reduced by 15% to bring the ICER to £50,000 
per QALY and by 76% to bring the ICER to £30,000 per QALY.  Pharmaceutical companies in 
agreement with Department of Health and NICE operate patient access schemes (PAS) to 
improve the cost-effectiveness of drugs. A PAS is proposed (i.e. a confidential discount 
rate) by the company with the aim of linking the price of the drug to decision makers WTP. 
No such transparent schemes are available to improve the cost-effectiveness of devices. 
Clearly, operating a flexible pricing scheme in any form will be a useful approach in 
considering LVAD as a BTT on the grounds of cost-effectiveness.  
 
Our study was part of the supporting evidence for NICE hip replacement and resurfacing 
multiple technology assessment. As a result of this work, NICE revised its current 
benchmark set at a 10% revision rate at 10 years to 5%. Our study found that the likely 
factors to influence revision are gender, age, head size, and device manufacturer. Our study 
also found that RS is not cost-effective over a lifetime for healthy patients and THR is 
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undoubtedly the most cost-effective option for all women and for men aged over 50 years 
old. The implication of our findings was that the use of suboptimal RS devices were 
removed or slowly phased out from routine NHS use.  
 
5.9. Future studies 
 
Some of the challenges faced in the economic evaluation of medical devices are rooted in 
the diversity of devices, as they encompass a wide range of products across a variety of 
health care settings. This diversity with rapid technological advancement pose challenges 
to centralise regulatory assessment of medical devices, and has allowed a large number of 
devices to slip into routine use without rigorous monitoring. Hence, existing regulatory 
framework should be centralised and improved for better patient safety.  
 
There are a number of technical challenges which would benefit from further work. Firstly, 
the accuracy of the long-term extrapolation of time-to-event data is constrained by the 
quality of the IPD used as the basis of extrapolation. In this thesis, we concentrated on 
commonly used parametric survival models, such as the exponential, lognormal and 
Weibull models, which make restrictive assumptions of the baseline hazard function, such 
as monotonicity. Although this thesis used Bathtub and flexible parametric models, work 
using other modelling approaches i.e. piece wise exponential framework using either a 
Bayesian or classical approach could offer greater flexibility to capture the observed data.  
 
Secondly, new designs of THRs and RSs have been introduced in the market without any 
comparative evidence demonstrating their superiority to existing devices. Hence, there is a 
strong need for randomised studies demonstrating the superiority of the different types of 
THR and RS prosthesis. When undertaking these randomised studies, emphasis should be 
on collecting better quantity and quality data for different type of prosthesis i.e. rate of 
revision; QoL and cost data; and patient and surgeon’s preference.  
 
National joint registries have played a significant part in monitoring and improving the 
outcomes for hip replacement and is one of the largest databases for hip replacement in 
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the world (National Joint Registry, 2016). Likewise, Australian Orthopaedic Association 
National Joint Replacement Registry and Swedish Hip Arthroplasty Register are two other 
established large national joint registries. However, there has been no noticeable joint 
working programme (i.e. joint publications; exchange programmes to learn on the data 
quality strategies; and learn from experience to reduce overall level of missing data) across 
these established national registries. Such future joint working programmes could be 
beneficial if considered.   
 
A major limitation of this study is that no RCT has yet been conducted comparing the long-
term survival of BTT with MM for patients eligible for HT. Therefore, we strongly 
recommend undertaking a prospective randomised trial comparing BTT with MM for 
patients eligible for HT. However, an RCT offering equal probability of HT for each group 
would not be feasible for ethical reasons. Hence, in the absence of such data, it is crucial to 
have a strong commitment to collect high quality real world evidence, including data on 
long-term patient survival, QoL, functional ability, adverse events and costs associated with 
second and third generation LVADs. It is necessary to give due consideration to ensure that 
the collection of real world evidence is fully updated with low overall level of missing data. 
5.10. Conclusions  
 
Our studies report the challenges faced in the economic evaluation of medical devices, and 
test the credibility of the cost-effectiveness estimates in a HTA framework. We have 
demonstrated methods to address these challenges: applications to the cost-effectiveness 
of BTT with LVAD compared to MM; and cost-effectiveness of five frequently used 
categories of THR; and cost-effectiveness of RS versus THR. However, practical 
implementation of these approaches to other devices could be limited due to the lack of 
good quality and quantity data on comparative treatment effectiveness, making economic 
evaluations challenging. The VAD and hip devices had long-term observational data for 
economic evaluation; whether or not establishing similar observational database becomes 
a regular component of device evaluation process depends on the affordability and 
practicality of establishing and maintaining such a database. Recently, the Department of 
Health has established “The Breast and Cosmetic Implant Registry following the Poly 
Implant Prosthese breast implant scandal in 2010 (Register, 2016). The DePuy RS device 
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did face similar challenges, and was recently withdrawn after unacceptably high revision 
rates. However, such an incident was well monitored and managed, as the registry 
provided an opportunity for the hospital to notify patients on the performance of their 
implant and to create awareness through patient organisations (Smith AJ, 2012). Whether 
or not mandatory database for all surgical implants will improve decision making and 
ultimately improve patient outcomes is not a question that could be answered until more 
such economic evaluations have been undertaken.  
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